BioXcel Therapeutics to Present at the 20th Annual HC Wainwright Global Investment Conference Aug 28, 2018
BioXcel Therapeutics Establishes Immuno-Oncology Clinical Advisory Board to Advance BXCL701 Development Aug 22, 2018
BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update Aug 8, 2018
BioXcel Therapeutics Strengthens Leadership Team with Industry Veteran Michael De Vivo Ph.D. as Vice President, Neuroscience Aug 7, 2018
BioXcel Therapeutics Enhances Leadership with Appointment of Vikas Sharma, Ph.D. as Vice President of Business Development Jul 31, 2018
DPP8/9 Inhibition - The Primary Mechanism of BioXcel Therapeutics’ Lead Immuno-Oncology Asset, BXCL701, Highlighted in Peer-Reviewed Journal Jul 24, 2018
BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501 Jul 10, 2018
BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine Supporting BXCL501 Development Jun 27, 2018
